Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update
Foghorn Therapeutics Inc. (FHTX)
Company Research
Source: GlobeNewswire
First patient dosed with first-in-class SMARCA2(BRM) selective inhibitor FHD-909 (LY4050784) in Phase 1 trial with primary target population in SMARCA4(BRG1) mutated NSCLC Topline Phase 1 dose escalation data for FHD-286 plus decitabine in patients with relapsed and/or refractory AML expected by year-end 2024 IND-enabling studies for Selective CBP degrader program on track to begin by year-end 2024 Strong balance sheet with cash, cash equivalents, and marketable securities of $267.4 million as of September 30, 2024, provides cash runway into 2027 CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the Company’s 10-Q filing for the quarter ended September 30, 2024. With an initial focus in oncology, Foghorn’s Gene Traffic Control®
Show less
Read more
Impact Snapshot
Event Time:
FHTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FHTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FHTX alerts
High impacting Foghorn Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
FHTX
News
- Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore BiotechnologiesPR Newswire
- Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with PfizerPR Newswire
- Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-PartnerPR Newswire
- Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori BioPR Newswire
- Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
FHTX
Earnings
- 11/4/24 - Beat
FHTX
Sec Filings
- 11/4/24 - Form 10-Q
- 11/4/24 - Form 8-K
- 10/10/24 - Form 8-K
- FHTX's page on the SEC website